02.02.2022 • NewsDr. Reddy'sPeople

Akhil Ravi Named CEO of Aurigene Pharmaceutical Services

Dr. Reddy's has appointed Akhil Ravi as CEO for its wholly-owned subsidiary Aurigene Pharmaceutical Services effective Feb. 1, 2022.

Since joining Dr. Reddy's in 2018 from McKinsey, Ravi has served as Head of Strategy for Services and Active Pharmaceutical Ingredients (APIs), and headed the Sales of APIs in Europe. He holds a BTech degree in Chemical Engineering from IIT Bombay and an MBA from the Indian School of Business (ISB).

Deepak Sapra, CEO of API and Services at Dr. Reddy’s and Member of the Board at Aurigene, said: "Akhil is very well prepared for this role. He was instrumental in growing our API business through product development and an improved service experience for our B2B customers through digital platforms. His strong background in customer service, sales, strategy, and management make him an ideal leader for Aurigene, and we look forward to his accomplishments in this new role."

"Aurigene Pharmaceutical Services is a dynamic partner for global pharma companies. With its integrated services from clinical research up to commercial manufacturing for small and large molecules, it is able to significantly speed up the journey of an NCE/NBE (New Chemical and Biological Entities) to the patient," Ravi added.

Akhil Ravi, CEO, Aurigene Pharmaceutical Services. Photo: Dr. Reddys
Akhil Ravi, CEO, Aurigene Pharmaceutical Services. Photo: Dr. Reddy's

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read